Navigation Links
Latest Addition to Patent Portfolio Hammers Prescription Drug Abuse and Creates New Market
Date:5/17/2011

ormulation techniques to solve complex problems. Pisgah has identified salt forms of nearly all the commercial opiates used in prescription pain medications which will impart abuse deterrent features. The drug abuser will find it more difficult to separate the active ingredient from the dosage form, and the active ingredient will be far less soluble in the abuse-route mucosa (nasal, vaginal, rectal). However, it is important to note, the drug will perform properly when used as intended by oral administration -- and when taken as prescribed, the release of the drug is not accelerated by drinking alcohol.

As for an integrated commercial offering covering other popular pain medications, Pisgah is continuing their research efforts while aggressively pursuing a development program for hydrocodone / acetaminophen combination products. In laboratory testing, Pisgah has shown they can "adjust" the properties of the new salts to yield immediate or controlled release versions. In general, the drug development pathway can be quite tortuous with unexpected events occurring, such as the FDA's mandate to reduce acetaminophen levels in products like Pisgah is developing. Fortunately, Pisgah sees this change more as an opportunity than a difficulty. As Pisgah's President, Bill Bristol, commented, "The mandated lower levels of acetaminophen allows for our technology's benefits to shine and not to be eclipsed by the health issues raised by higher levels of acetaminophen in combination products."

With eighteen patent applications and more on the way, Pisgah's intellectual property stable continues to grow, and is applicable to dozens of abused prescription drugs. Pisgah's technology provides an integrated solution to three principal concerns within the medical community: 1) improving patient care; 2) reducing medical practice liability; and 3) reducing barriers for treating pain. Pisgah anticipates its new products will be well-received by all stakeholders interested i
'/>"/>

SOURCE Pisgah Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NEURO-BIOTECH CORPORATION: Updates and latest developments
2. Former FDA Inspectors Train Medical Device, Pharmaceutical Companies How to Comply with Latest FDA Expectations for Validation and Part 11
3. Micro rheometer is latest Lab On a Chip device
4. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
5. CBR Pharma Insights' Latest Report, The New Era of Healthcare Reform - Supporting Revenue Growth through Understanding & Adaptation
6. Latest breakthroughs in technology expand options for diagnosing and treating disease
7. Healthcare Data Solutions Announces Latest Database, PrescriberPRO@Home.
8. The Latest in Digital USB Microscopes from Cole-Parmer
9. New STR Systems from Promega Comply with Latest DNA Database Standards
10. LS9 Secures $25 Million in Latest Round of Funding
11. World Renowned Scientists Gather to Share Latest Information on Answer to Wildlife Reproductive Fertility Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that its three Promissory ... Portage, who advanced $ 100,000 each in July 2014 ... their Notes and related Coupons converted into 3,500,001 restricted ... carried 5% coupon. Both the Note and the coupon ...
(Date:9/29/2014)... , Sept. 29, 2014 Research ... "Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph Market ... & Region - Global Trends & Forecast to 2013 ... A process analyzer is a process analytical instrument ... real-time. It has redefined the way by which companies ...
(Date:9/29/2014)... ACEA Biosciences, Inc. (ACEA) has ... iCELLigence Research Grant for his proposal on cancer ... an impedance based real-time label-free cellular analysis instrument. ... Biomedical Engineering at Yale University currently holds a ... Professor Rong Fan's laboratory involve the ...
(Date:9/29/2014)... - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a ... and products for advanced microarray diagnostics, is pleased to ... Chairman of the Board of Directors of SQI, replacing ... serve as a Director on the Board and will ... "We are very pleased to have Mr. Winkley ...
Breaking Biology Technology:Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2SQI Diagnostics Announces New Chairman of Board of Directors 2
... /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin ... of the leading plasma-based pharmaceutical companies,in the ... that the Company,received approval from the PRC ... commence clinical trial of its new Human ...
... Cytotoxic ... Compound Market, ... development organization supporting the,pharmaceutical industry -- today announced the opening ... The 18,000 sq. ft. facility includes newly constructed analytical and,formulation ...
... (Nasdaq: SGMO ) announced today that Edward Lanphier,Sangamo,s ... progress of,Sangamo,s ZFP Therapeutic development programs and an overview ... Tuesday, September 23,2008, at the 2008 UBS Global Life ... will be webcast live and may be accessed via ...
Cached Biology Technology:China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 2China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 3Pharmatek Announces Official Opening of New Highly-Potent & Cytotoxic Development and Manufacturing Facility 2Sangamo BioSciences to Present at the UBS Global Life Sciences Conference 2
(Date:9/29/2014)... . Montreal, ... expectant mother was deprived of electricity during Quebec,s Ice ... a new study finds., Scientists from the Douglas Mental ... distinctive ,signature, in the DNA of children born in ... months after the event, researchers recruited women who had ...
(Date:9/29/2014)... Sclerosis (MS) were able to safely tolerate treatment with ... study published today in the journal Multiple Sclerosis ... first of its kind, was conducted by researchers at ... and collaborators at several other institutions. , While ... in the data also suggested that a preparation of ...
(Date:9/27/2014)... The first direct comparison of treating non-squamous lung ... to cisplatin has shown that the two combinations ... with more frequent adverse events. , At the ... from Chonnam National University Medical School, South Korea, ... trial that included 149 patients with non-squamous non-small ...
Breaking Biology News(10 mins):Cells from placentas safe for patients with multiple sclerosis 2Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca 2
... molecule made by the human body that triggers the immune ... to new research published today in Nature Medicine . ... that if scientists could block this signal, it may be ... is the most common autoimmune disease, affecting around 1 in ...
... canopies bear little resemblance to their seedlings, many described ... "Seedlings of Barro Colorado Island and the Neotropics," published ... Garwood, professor of plant biology at the University of ... describing seedling stages of tropical plants 25 years ago ...
... Lieberman (I-CT) and John Cornyn (R-TX) today introduced the ... ensure free, timely, online access to the published results ... proposed bill is welcomed by the Alliance for Taxpayer ... others formed to support open public access to publicly ...
Cached Biology News:New trigger for chronic inflammation in rheumatoid arthritis discovered 2New guide to tropical seedlings: Essential to climate change research 2Taxpayer Alliance applauds bill to broaden access to federal research results 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,381-3) ...
...
... Gel loading buffer is especially formulated for ... nucleic acids. The gel loading solution contains ... to add density and facilitate sample loading. ... that require divalent cations and SDS has ...
Biology Products: